The Zacks Analyst Blog Highlights: McGraw-Hill, Moody's, Gilead Sciences, Abbott Labs and Bristol-Myers Squibb

  The Zacks Analyst Blog Highlights: McGraw-Hill, Moody's, Gilead Sciences,
                     Abbott Labs and Bristol-Myers Squibb

PR Newswire

CHICAGO, Nov. 19, 2012

CHICAGO, Nov. 19, 2012 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include The McGraw-Hill Companies, Inc.
(NYSE:MHP), Moody's Corp. (NYSE:MCO), Gilead Sciences (Nasdaq:GILD), Abbott
Labs (NYSE:ABT), Bristol-Myers Squibb (NYSE:BMY).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday's Analyst Blog:

A Balanced Solution to the Cliff?

The primary concern for investors remains the 'fiscal cliff'. Under the worst
case scenario of gridlock in Washington, D.C., some $600 billion in tax hikes
and expenditure cuts will go into effect in early 2013. Under these
circumstances a feeble U.S. economy would go once again into recession.

One negative outcome of all this uncertainty is that U.S. companies, despite
rock-bottom interest rates, have hoarded about $1.7 trillion in cash. Judging
from the performance of the U.S. markets lately, investors may be spooked by a
possible increase in taxes on dividend and capital gains.

On Thursday, President Obama reiterated that he would not roll over tax cuts
for the wealthiest Americans. The problem is that implementing the President's
tax ideas do not come anywhere near plugging the deficit. For example, taxing
the rich and getting rid of tax breaks for corporations would only make a dent
on the mammoth deficit.

It is in this context that a report by Erskine Bowles and former Senator Alan
Simpson assumes center stage. They have suggested a calibrated approach for
bringing down the trillion dollar plus annual budget deficit. The two
recommend a combination of spending cuts and tax increases.

The duo has suggested reform in five critical areas: trimming healthcare
expenses (which may consume as much as 25% of GDP), reforming social security
(people are living a lot longer today than at the time when the system was
devised), curtailing the defense bill, reforming the tax laws and managing the
ever growing compound interest burden on the national debt.

While a solution to the impasse would be the favored approach, we recognize
that there is a possibility that a bi-partisan compromise may not be reached.
In that case, the Administration may simply claim that the national interest
was subverted by the taxes on the rich debate. In any case, following the
demise of the Bush era tax cuts, the Administration would get to collect some
of the sought-after revenue.

Credit rating agencies must contend with the current uncertainty. Standard &
Poor's Rating Services, a part of The McGraw-Hill Companies, Inc. (NYSE:MHP)
currently retains a AA+ local and foreign currency rating. Moody's Corp.
(NYSE:MCO) has a negative outlook on the U.S. at present.

Gilead Presents Encouraging Data

Gilead Sciences (Nasdaq:GILD) recently presented encouraging long-term data on
its HIV therapy Stribild from two ongoing phase III studies (102 and 103) as a
first-line therapy. Data from study 102 revealed that Stribild was
non-inferior to Gilead's Atripla after two years of treatment.

Data from study 103 demonstrated the non inferiority of Stribild to Norvir
(ritonavir)-boosted Reyataz plus Truvada after a similar time period. While
Norvir is marketed by Abbott Labs (NYSE:ABT), Reyataz is marketed by
Bristol-Myers Squibb (NYSE:BMY). Gilead presented the encouraging results at
the 11th international congress on drug therapy regarding HIV infection in the
UK.

We note that Stribild, a combination pill, is a new addition to Gilead's
formidable HIV franchise. The drug was approved by the US Food and Drug
Administration (FDA) in August 2012 as a first-line therapy for treating
adults suffering from HIV. The approval was based on encouraging 48 weeks data
from studies 102 and 103. Stribild is under review for the same indication in
the EU.

Neutral on Gilead

We currently have a Neutral recommendation on Gilead. The stock carries a
Zacks #3 Rank (Hold rating) in the short run. We remain optimistic on the
growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also
encouraged by the sales ramp of Complera/Eviplera, which together with
Stribild, has further fortified the HIV franchise and helped to mitigate the
impact of upcoming patent expirations.

Gilead is looking to combat the threat of genericization by inking deals,
making acquisitions and introducing new products. To further strengthen its
hepatitis C virus portfolio, Gilead purchased Pharmasset earlier in the year,
for approximately $11.1 billion.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks 

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com